PASG Share Price | Passage Bio, Inc. Stock Analysis & Recommendation

Q: What does Passage Bio, Inc. do?

Overview: Passage Bio, Inc. is a preclinical stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) Market cap: USD 23.65 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.28 Return on Equity: -119.02% Price to Book: 0.51Contact Details: Address: TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR PHILADELPHIA PA : 19103 Tel: 1 267 8660312 Fax: 1 302 6555049 Website: https://www.passagebio.com/

Q: Is Passage Bio, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Passage Bio, Inc. has changed from bullish to mildly bullish. The MACD indicates a mildly bullish stance on both the weekly and monthly time frames, while the Dow Theory shows a mildly bullish signal on the weekly chart. However, the moving averages are mildly bearish on the daily time frame, and the KST and OBV are bearish or showing no trend, respectively, on the weekly and monthly charts. In terms of performance, the stock has returned 8.32% over the past week and 4.57% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% in the same periods. However, the longer-term returns are significantly negative, with a year-to-date return of -33.43% compared to the S&P 500's 12.22%, and a one-year return of -46.15% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals across different indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.37 k

Shareholding (Sep 2025)

FII

22.05%

Held by 15 FIIs

DII

52.56%

Held by 6 DIIs

Promoter

20.02%

How big is Passage Bio, Inc.?

22-Jun-2025

As of Jun 18, Passage Bio, Inc. has a market capitalization of 23.65 million and reported net sales of 0.00 million with a net profit of -63.45 million for the latest four quarters. As of Dec 24, shareholder's funds were 61.26 million and total assets were 102.41 million.

View full answer

What does Passage Bio, Inc. do?

22-Jun-2025

Passage Bio, Inc. is a preclinical stage genetic medicines company focused on developing therapies for rare, monogenic central nervous system diseases. It has a market cap of $23.65 million and reported a net profit loss of $15 million as of March 2025.

View full answer

Who are in the management team of Passage Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Passage Bio, Inc. includes Dr. Tadataka Yamada (Independent Chairman), Dr. Bruce Goldsmith (CEO), Dr. Stephen Squinto (Acting Head of R&D), and several independent directors, bringing diverse expertise to the biotechnology sector.

View full answer

Is Passage Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Passage Bio, Inc. shows a mildly bullish trend overall, with mixed technical indicators and recent performance outperforming the S&P 500, but it has significantly negative long-term returns.

View full answer

Compare Passage Bio, Inc. with Similar Stocks

LAVA Therapeutics NV Precision BioSciences, Inc.Quince Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 38 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.58

Return on Equity

-136.98%

Price to Book

1.24

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

37.2%

6 Months

58.71%

1 Year

-25.33%

2 Years

-55.34%

3 Years

487.74%

4 Years

-90.31%

5 Years

-97.92%

Passage Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

3.33%

EBIT to Interest (avg)

-117.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.28

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

66.65%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

0.55

EV to EBITDA

0.57

EV to Capital Employed

2.57

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

468.40%

ROE (Latest)

-119.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 6 Schemes (5.37%)

Foreign Institutions

Held by 15 Foreign Institutions (22.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 41.25% vs 33.05% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.10",
          "val2": "-16.10",
          "chgp": "37.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.40",
          "val2": "-16.00",
          "chgp": "41.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.53% vs 24.98% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-62.10",
          "val2": "-96.40",
          "chgp": "35.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.20",
          "val2": "-7.80",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-64.80",
          "val2": "-102.10",
          "chgp": "36.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.10

-16.10

37.27%

Interest

0.00

Exceptional Items

0.00

-0.40

100.00%

Consolidate Net Profit

-9.40

-16.00

41.25%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 41.25% vs 33.05% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-62.10

-96.40

35.58%

Interest

0.00

Exceptional Items

-5.20

-7.80

33.33%

Consolidate Net Profit

-64.80

-102.10

36.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.53% vs 24.98% in Dec 2023

All Annual Results

Company CV

About Passage Bio, Inc.

Passage Bio, Inc.

Pharmaceuticals & Biotechnology

Passage Bio Inc is a preclinical stage genetic medicines company. The Company is focused on developing transformative therapies for rare, monogenic central nervous system (CNS). The Company is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The Company's products pipeline includes PBGM01 for the treatment of gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD), and PBKR03 for the treatment of Krabbe disease. The Company’s products PBGM01, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (beta-gal), PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), and PBKR03, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC).

Company Coordinates

Company Details

TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR PHILADELPHIA PA : 19103

Tel: 1 267 8660312

https://www.passagebio.com/

Registrar Details

Passage Bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Passage Bio, Inc.?

Watch in Real-Time

What does Passage Bio, Inc. do?

Who are in the management team of Passage Bio, Inc.?

Is Passage Bio, Inc. technically bullish or bearish?

Compare Passage Bio, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Passage Bio, Inc.

Company Coordinates